- Home
- CNTX vs CLYM Comparison
CNTX vs CLYM Comparison
Compare CNTX & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- CLYM
- Stock Information
- Founded
- CNTX 2015
- CLYM 2018
- Country
- CNTX United States
- CLYM United States
- Employees
- CNTX N/A
- CLYM N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- CNTX Health Care
- CLYM
- Exchange
- CNTX Nasdaq
- CLYM NYSE
- Market Cap
- CNTX 78.0M
- CLYM 86.5M
- IPO Year
- CNTX 2021
- CLYM 2021
- Fundamental
- Price
- CNTX $0.63
- CLYM $1.22
- Analyst Decision
- CNTX Strong Buy
- CLYM Buy
- Analyst Count
- CNTX 5
- CLYM 1
- Target Price
- CNTX $5.50
- CLYM $10.00
- AVG Volume (30 Days)
- CNTX 330.3K
- CLYM 403.6K
- Earning Date
- CNTX 08-06-2025
- CLYM 08-13-2025
- Dividend Yield
- CNTX N/A
- CLYM N/A
- EPS Growth
- CNTX N/A
- CLYM N/A
- EPS
- CNTX N/A
- CLYM N/A
- Revenue
- CNTX N/A
- CLYM N/A
- Revenue This Year
- CNTX N/A
- CLYM N/A
- Revenue Next Year
- CNTX N/A
- CLYM N/A
- P/E Ratio
- CNTX N/A
- CLYM N/A
- Revenue Growth
- CNTX N/A
- CLYM N/A
- 52 Week Low
- CNTX $0.49
- CLYM $1.05
- 52 Week High
- CNTX $2.75
- CLYM $9.21
- Technical
- Relative Strength Index (RSI)
- CNTX 50.76
- CLYM N/A
- Support Level
- CNTX $0.62
- CLYM N/A
- Resistance Level
- CNTX $0.70
- CLYM N/A
- Average True Range (ATR)
- CNTX 0.05
- CLYM 0.00
- MACD
- CNTX 0.01
- CLYM 0.00
- Stochastic Oscillator
- CNTX 56.44
- CLYM 0.00
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.